BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, May 10, 2024
See today's BioWorld
Home
» Roche Pays Gilead $62.5M To Settle Tamiflu Dispute
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Roche Pays Gilead $62.5M To Settle Tamiflu Dispute
Nov. 17, 2005
By
Randy Osborne
No Comments
To more quickly "address [the] global public health need" of a vaccine against the avian flu, Gilead Sciences Inc. and F. Hoffmann-La Roche Ltd. are ending their dispute over Tamiflu, and $62.5 million is changing hands. (BioWorld Today)
BioWorld